Nalphin20 mg/2 ml

Nalphin 20 mg/2 ml hydrochloride is an injectable opioid analgesic used for:

• Management of moderate to severe pain
• As a supplement to balanced anaesthesia, before and during surgical procedures
• Preoperative and postoperative analgesia
• Obstetrical analgesia during labour and delivery

Contains Nalphin 20 mg/2 ml hydrochloride as the active ingredient, available as an injectable solution, commonly in 10 mg/mL and 20 mg/mL strengths, for intramuscular, subcutaneous, or intravenous use.

Nalphin 20 mg/2 ml is an injectable opioid analgesic with a mixed agonist-antagonist profile: it activates kappa opioid receptors (producing pain relief) while blocking mu opioid receptors (the receptors most associated with the euphoria, dependence, and severe respiratory depression risk of typical opioids like morphine). This distinctive profile gives Nalphin 20 mg/2 ml a "ceiling effect" for respiratory depression - increasing the dose beyond about 30 mg does not cause further breathing suppression, when used alone. However, this same antagonist activity means Nalphin 20 mg/2 ml can precipitate withdrawal symptoms in patients who are physically dependent on other opioids, and it carries an important boxed warning regarding the risk of serious, potentially fatal breathing problems when combined with benzodiazepines or other central nervous system depressants.

Therapeutic Class: Opioid Analgesic (Mixed Agonist-Antagonist)

Nalphin 20 mg/2 ml's analgesic potency is approximately equivalent to morphine on a milligram basis up to a dose of about 30 mg. Unlike pure mu-agonist opioids, it exhibits a ceiling effect for respiratory depression, meaning doses greater than 30 mg do not produce further breathing suppression in the absence of other central nervous system-active medicines affecting respiration. Its opioid antagonist activity is one-fourth as potent as nalorphine and ten times that of pentazocine, and its own respiratory depressant effects can still be reversed by naloxone.

• Administered only by a healthcare professional, by intramuscular, subcutaneous, or intravenous injection
• Patients are advised not to drive or operate heavy machinery after receiving Nalphin 20 mg/2 ml, given its sedative and analgesic central nervous system effects
• Limit dosages and durations to the minimum required for the clinical situation
• Monitor for signs and symptoms of respiratory depression and sedation, particularly at treatment initiation or following a dose increase

The following interactions are important, particularly the boxed warning regarding benzodiazepines:

• Benzodiazepines and other CNS depressants (boxed warning): concomitant use can result in profound sedation, respiratory depression, coma, and death; reserve concomitant use for patients with no alternative, use the lowest effective doses for the shortest duration, and monitor closely for sedation and respiratory depression.
• Other opioid analgesics, alcohol, sedatives, and other CNS depressants: additive sedation and respiratory depression risk.
• Mu-agonist opioids (such as morphine, fentanyl, or oxymorphone) given before or concurrently with Nalphin 20 mg/2 ml: Nalphin 20 mg/2 ml may partially reverse or block the analgesic and respiratory-depressant effects of these mu-agonist opioids, given its antagonist activity at the mu receptor.
• Patients physically dependent on opioids: Nalphin 20 mg/2 ml may precipitate an acute opioid withdrawal syndrome, given its mu-antagonist properties; use with caution in this population, and consider a reduced starting dose.
• Monoamine oxidase inhibitors (MAOIs): use with caution, given the potential for unpredictable interactions seen with opioid-class medicines and MAOIs.

Common side effects

• Sedation, drowsiness
• Sweating, clammy skin
• Nausea, vomiting
• Dizziness, vertigo
• Dry mouth
• Headache
• Miosis (constricted pupils, even in darkness)

Serious side effects (require prompt medical attention)

• Respiratory depression: particularly if combined with benzodiazepines, alcohol, or other CNS depressants; can be life-threatening.
• Opioid withdrawal symptoms in patients dependent on other opioids: agitation, sweating, abdominal cramping, diarrhoea, restlessness.
• Opioid-induced hyperalgesia (increased pain sensitivity), reported with both short-term and prolonged use.
• Signs of a severe allergic reaction: rash, swelling, difficulty breathing.

Pregnancy

Nalphin 20 mg/2 ml is used for obstetrical analgesia during labour and delivery under medical supervision; use earlier in pregnancy, or for other indications, should be discussed with a doctor, weighing the benefits and risks, since prolonged opioid use during pregnancy can be associated with neonatal withdrawal in the newborn.

Breastfeeding

Nalphin 20 mg/2 ml passes into breast milk in small amounts; use during breastfeeding should be discussed with a healthcare professional, with the nursing infant monitored for sedation or feeding difficulties.

• Boxed warning - concomitant use with benzodiazepines or other CNS depressants: can result in profound sedation, respiratory depression, coma, and death; reserve for patients where alternative treatment options are inadequate.
• Respiratory depression: monitor closely, particularly in patients with underlying respiratory conditions or those receiving other CNS depressants.
• Opioid dependence: use with caution in patients on regular mu-agonist opioid therapy, given the risk of precipitating withdrawal; a reduced starting dose is generally used in this population.
• Advise patients not to drive or operate hazardous machinery after receiving Nalphin 20 mg/2 ml.
• Use with caution in patients with head injury or raised intracranial pressure, given the potential for opioids to mask clinical signs in these patients.

Overdose can cause respiratory depression, sedation, low blood pressure, and, in severe cases, coma. While Nalphin 20 mg/2 ml has a ceiling effect for respiratory depression when used alone at higher doses, this ceiling does not protect against depression caused by combining it with other CNS depressants such as benzodiazepines, alcohol, or other opioids. Naloxone can reverse Nalphin 20 mg/2 ml's respiratory depressant effects. Suspected significant overdose is a medical emergency requiring immediate treatment; seek emergency care immediately.

Store at controlled room temperature, protected from light, as directed on the product label. Store securely, given its status as a controlled substance in some jurisdictions and its potential for misuse.

• Elderly: May be more sensitive to the sedative and respiratory effects of opioids; use with a cautious starting dose and close monitoring.
• Hepatic or renal impairment: Use with caution, given altered drug clearance in these populations; dose adjustment may be needed.
• Patients with opioid dependence: Require a reduced dose (approximately 25% lower) and close observation for withdrawal symptoms.

Nalphin 20 mg/2 ml is generally used for short-term, acute pain management, such as during surgery, postoperative recovery, or labour and delivery. Limit dosages and durations to the minimum required for the clinical situation, given the potential for tolerance and dependence with prolonged opioid use.

Drug Class: Synthetic opioid agonist-antagonist (kappa agonist, mu antagonist)

Nalphin 20 mg/2 ml works as an agonist at kappa opioid receptors, which produces analgesia, while simultaneously acting as an antagonist at mu opioid receptors, the receptors most responsible for the strong euphoria, dependence potential, and severe respiratory depression seen with pure opioid agonists like morphine or fentanyl. This mixed action gives Nalphin 20 mg/2 ml pain-relieving properties with a ceiling on respiratory depression at doses above about 30 mg when used alone, and means it can partially reverse or block respiratory depression from a mu-agonist opioid given concurrently, while also being able to precipitate withdrawal in patients already dependent on mu-agonist opioids.

No specific pediatric dosing has been well established in official labeling; use in children should only occur under specialist medical supervision, with dosing individualized based on the child's weight and clinical situation.